14 min listen
Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study
FromRMD Open Podcast
ratings:
Length:
17 minutes
Released:
Jul 15, 2022
Format:
Podcast episode
Description
In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process.
Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236
(1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)
Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236
(1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)
Released:
Jul 15, 2022
Format:
Podcast episode
Titles in the series (17)
Interleukin-17: a role in inflammatory arthritis and implication for clinical practice by RMD Open Podcast